These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7489199)

  • 1. Opportunities and obstacles in the implementation of barrier technology.
    Agalloco J
    PDA J Pharm Sci Technol; 1995; 49(5):244-8. PubMed ID: 7489199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDA comments: PIC draft recommendations on the inspection of isolator technology. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1999; 53(3):141-7. PubMed ID: 10754704
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential for use of steam at atmospheric pressure to decontaminate or sterilize parenteral filling lines incorporating barrier isolation technology.
    Lysfjord JP; Haas PJ; Melgaard HL; Pflug IJ
    PDA J Pharm Sci Technol; 1995; 49(5):212-9. PubMed ID: 7489194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the BioVigilant IMD-A, a novel optical spectroscopy technology for the continuous and real-time environmental monitoring of viable and nonviable particles. Part II. Case studies in environmental monitoring during aseptic filling, intervention assessments, and glove integrity testing in manufacturing isolators.
    Miller MJ; Walsh MR; Shrake JL; Dukes RE; Hill DB
    PDA J Pharm Sci Technol; 2009; 63(3):259-83. PubMed ID: 20069799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
    Paciorek CJ; Liu Y;
    Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of clean room design on product contamination.
    Whyte W
    J Parenter Sci Technol; 1984; 38(3):103-8. PubMed ID: 6747777
    [No Abstract]   [Full Text] [Related]  

  • 9. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
    J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigational trends: clean room environmental monitoring.
    Tetzlaff RF
    J Parenter Sci Technol; 1992; 46(6):206-14. PubMed ID: 1474432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory aspects of isolation/barrier technology.
    Lyda JC
    PDA J Pharm Sci Technol; 1995; 49(6):300-4. PubMed ID: 8581462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspective: Challenges in the Aerospace Marketplace and Growth Opportunities for Thermal Spray.
    Dorfman MR; Dwivedi G; Dambra C; Wilson S
    J Therm Spray Technol; 2022; 31(4):672-684. PubMed ID: 37520273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical report: bioburden recovery validation. PDA Bioburden Recovery Validation Task Force. Parenteral Drug Association.
    J Parenter Sci Technol; 1990; 44(6):324-31. PubMed ID: 2277321
    [No Abstract]   [Full Text] [Related]  

  • 14. Developing an information systems strategy for nursing.
    Callanan KM; Hughes SJ
    Medinfo; 1995; 8 Pt 2():1419. PubMed ID: 8591465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design control and validation of a facility for sterile clinical trial preparations.
    Staines L
    J Parenter Sci Technol; 1984; 38(3):109-14. PubMed ID: 6747778
    [No Abstract]   [Full Text] [Related]  

  • 16. Environmental microbial challenges to an aseptic Blow-Fill-Seal process--a practical study.
    Jones DJ; Topping P; Sharp J
    PDA J Pharm Sci Technol; 1995; 49(5):226-34. PubMed ID: 7489196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovation in industry and the diffusion of technology.
    Utterback JM
    Science; 1974 Feb; 183(4125):620-6. PubMed ID: 17778831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparing a business justification for going electronic.
    Ortiz AO; Luyckx MP
    Radiol Manage; 2002; 24(1):14-21. PubMed ID: 11857990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active air vs. passive air (settle plate) monitoring in routine environmental monitoring programs.
    Andon BM
    PDA J Pharm Sci Technol; 2006; 60(6):350-5. PubMed ID: 17260900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDA comments: SUPAC-IR, ICH Q1C, FDA draft guideline. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(4):152-6. PubMed ID: 7552232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.